Clinical Trial Update: Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial update reports safety and pharmacokinetics data for a 1500 mg single dose of famciclovir in adolescents with recurrent herpes labialis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpes Labialis

Drugs mentioned

• Famciclovir (famciclovir)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Herpes Labialis | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2021-06-25